Skip to main content
. 2018 Apr 6;114(10):1350–1359. doi: 10.1093/cvr/cvy064

Figure 5.

Figure 5

Early resveratrol co-administration with DOX results in beneficial effects later in life. (A) Scheme of study design for investigating the long-term effects of resveratrol co-administration after Ang II–induced hypertension later in life. (B) SBP (n = 5–6), (C) LVPWd (n = 5–8), (D) HW/TL (n = 6–7), (E) LV internal dimension in diastole (LVDd, n = 5–8), (G) LV end-diastolic volume (LVEDV, n = 5–8), (F) stroke volume (n = 5–8), and (H) cardiac output (n = 5–8) after the low dose of Ang II. *P < 0.05 between groups indicated. Values are presented as mean ± SEM and analysed by two-way ANOVA with Bonferroni post hoc test. (I) Heat map illustrating the changes in expression of p53 effector genes by DOX alone or resveratrol co-administration with DOX at 1 week after the last DOX injection (1 week post-DOX) and after 2 weeks of continuous Ang II infusion (after Ang II). CON indicates control; D + R indicates resveratrol co-administration with DOX.